Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Antiviral Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Nucleolin (NCL) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Nucleolin (NCL) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View Nucleolin Products |
| Gene Delivery | Nucleolin (NCL) Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to study cell-surface translocation. |
View Nucleolin Products |
| Benchmark Ab | Anti-Nucleolin Recombinant Antibody Recombinant positive control for binding, internalization, and immunofluorescence assays. |
View Nucleolin Products |
| Validator | Nucleolin (NCL) siRNA Set Target-specific knockdown verification in functional assays. |
View Nucleolin Products |
| Related Target A | EGFR Nucleolin physically interacts with EGFR on the cell surface, promoting receptor activation and downstream oncogenic signaling. |
View EGFR Products |
| Related Target B | VEGFR2 Cell-surface nucleolin serves as a co-receptor for VEGF, modulating tumor angiogenesis and endothelial cell migration. |
View VEGFR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing surface vs. nuclear Nucleolin | Lentivirus-mediated stable cell lines for live-cell flow cytometry and immunofluorescence without permeabilization |
| Post-translational modification dependency | HEK293 mammalian expression system ensuring authentic phosphorylation and glycosylation patterns |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live Nucleolin (NCL) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Nucleolin therapeutics is intensifying, with major players shifting focus from traditional aptamers to antibody-drug conjugates (ADCs) and targeted radiopharmaceuticals. As first-generation therapies like AS1411 paved the way for targeting cell-surface nucleolin, the next wave of R&D is targeting tumor-specific post-translational modifications and utilizing nucleolin as an internalization receptor for cytotoxic payloads.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Academic Institutions, Biotech Startups | Solid Tumors, Triple-Negative Breast Cancer | Internalization Assay (Need high-purity ECD-Fc) |
| Aptamer-Drug Conjugates (ApDC) | Aptamer Therapeutics Developers | Glioblastoma, Acute Myeloid Leukemia (AML) | High-affinity binding assays (Need sequence-verified NCL protein) |
| CAR-T / Cell Therapy | Immunotherapy Pioneers | Refractory Hematological Malignancies | Cell-based binding and activation assays (Need Lentivirus for stable lines) |